Basic Information
| LncRNA/CircRNA Name | CASC2 |
| Synonyms | CASC2, C10orf5 |
| Region | GRCh38_10:118046279-118210153 |
| Ensemble | ENSG00000177640 |
| Refseq | NR_026939 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | temozolomide(TMZ) | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Luciferase reporter assay, Western blot |
| Sample | glioma tissues, cell lines (U257 and U87) |
| Expression Pattern | down-regulated |
| Function Description | CASC2 is downregulated in gliomas, resulting in increased miR-193a-5p level and a decrease in mTOR expression, which further induces protective autophagy, leading to TMZ resistance. Inhibition of autophagy helps to increase the efficacy of TMZ. |
| Pubmed ID | 29136760 |
| Year | 2017 |
| Title | Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression. |
External Links
| Links for CASC2 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |